Researchers at the Stanford University School of Medicine and their colleagues have developed a way to pinpoint potential targets for cancer therapies that rely on the body’s immune system. Those targets are molecules called antigens, which appear on the surface of tumor cells and other malignant or damaged cells. Antigens are cumbersome to identify but critical to developing cancer immunotherapies, a type of treatment in which the host’s own immune system is trained to seek out and fight harmful or mutated cells. And while cancer vaccines are still largely a thing of the future, new antigens are key to nudging progress forward.
See original article at: https://www.sciencedaily.com/releases/2017/12/171221122600.htm